GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Gross Profit

ORKA (Oruka Therapeutics) Gross Profit : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Gross Profit?

Oruka Therapeutics's gross profit for the six months ended in Mar. 2024 was $0.00 Mil. Oruka Therapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Oruka Therapeutics's gross profit for the six months ended in Mar. 2024 was $0.00 Mil. Oruka Therapeutics's Revenue for the six months ended in Mar. 2024 was $0.00 Mil. Therefore, Oruka Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Oruka Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Oruka Therapeutics Gross Profit Historical Data

The historical data trend for Oruka Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Gross Profit Chart

Oruka Therapeutics Annual Data
Trend
Gross Profit

Oruka Therapeutics Semi-Annual Data
Mar24
Gross Profit -

Competitive Comparison of Oruka Therapeutics's Gross Profit

For the Biotechnology subindustry, Oruka Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oruka Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Gross Profit falls into.



Oruka Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Oruka Therapeutics's Gross Profit for the fiscal year that ended in . 20 is calculated as

Gross Profit (A: . 20 )=Revenue - Cost of Goods Sold
= -
=0.00

Oruka Therapeutics's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Oruka Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Oruka Therapeutics  (NAS:ORKA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Oruka Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Oruka Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
Address
221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453
Website
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.